ΑΙhub.org
 

Prediction of drug metabolites using deep learning


by
29 December 2020



share this:
A computational tool created at Rice University may help pharmaceutical companies expand their ability to investigate the safety of drugs. (Credit: Kavraki Lab/Rice University)

By Mike Williams
AIhub focus issue on good health and well-being
When you take a medication, you want to know precisely what it does. Pharmaceutical companies go through extensive testing to ensure that you do. With a new deep learning-based technique created at Rice University’s Brown School of Engineering, they may soon get a better handle on how drugs in development will perform in the human body.

Lydia Kavraki, Professor of Computer Science, has introduced Metabolite Translator, a computational tool that predicts metabolites, the products of interactions between small molecules like drugs and enzymes.

Lydia Kavraki

Lydia Kavraki. (Credit: Jeff Fitlow/Rice University)

The Rice researchers take advantage of deep-learning methods and the availability of massive reaction datasets to give developers a broad picture of what a drug will do. The method is unconstrained by rules that companies use to determine metabolic reactions, opening a path to novel discoveries.

“When you’re trying to determine if a compound is a potential drug, you have to check for toxicity,” Kavraki said. “You want to confirm that it does what it should, but you also want to know what else might happen.”

The research by Kavraki, lead author and graduate student Eleni Litsa and Rice alumna Payel Das (IBM), is detailed in the Royal Society of Chemistry journal Chemical Science.

The researchers trained Metabolite Translator to predict metabolites through any enzyme, but measured its success against the existing rules-based methods that are focused on the enzymes in the liver. These enzymes are responsible for detoxifying and eliminating xenobiotics, like drugs, pesticides and pollutants. However, metabolites can be formed through other enzymes as well.

“Our bodies are networks of chemical reactions,” Litsa said. “They have enzymes that act upon chemicals and may break or form bonds that change their structures into something that could be toxic, or cause other complications. Existing methodologies focus on the liver because most xenobiotic compounds are metabolized there. With our work, we’re trying to capture human metabolism in general.

“The safety of a drug does not depend only on the drug itself but also on the metabolites that can be formed when the drug is processed in the body,” Litsa said.

The rise of machine learning architectures that operate on structured data, such as chemical molecules, make the work possible, she said. The Transformer was introduced in 2017 as a sequence translation method that has found wide use in language translation.

Metabolite Translator is based on SMILES (for “simplified molecular-input line-entry system”), a notation method that uses plain text rather than diagrams to represent chemical molecules.

Eleni Litsa

Eleni Litsa. (Credit: Rice University)

“What we’re doing is exactly the same as translating a language, like English to German,” Litsa said.

Due to the lack of experimental data, the lab used transfer learning to develop Metabolite Translator. They first pre-trained a Transformer model on 900,000 known chemical reactions and then fine-tuned it with data on human metabolic transformations.

The researchers compared Metabolite Translator results with those from several other predictive techniques by analyzing known SMILES sequences of 65 drugs and 179 metabolizing enzymes. Though Metabolite Translator was trained on a general dataset not specific to drugs, it performed as well as commonly used rule-based methods that have been specifically developed for drugs. But it also identified enzymes that are not commonly involved in drug metabolism and were not found by existing methods.

“We have a system that can predict equally well with rule-based systems, and we didn’t put any rules in our system that require manual work and expert knowledge,” Kavraki said. “Using a machine learning-based method, we are training a system to understand human metabolism without the need for explicitly encoding this knowledge in the form of rules. This work would not have been possible two years ago.”

Kavraki is the Noah Harding Professor of Computer Science, a professor of bioengineering, mechanical engineering and electrical and computer engineering and director of Rice’s Ken Kennedy Institute. Rice University and the Cancer Prevention and Research Institute of Texas supported the research. View her research group webpage here.

Read the research article:

Prediction of drug metabolites using neural machine translation
Eleni E. Litsa, Payel Das and Lydia E. Kavraki



tags: ,


Rice University

            AIhub is supported by:



Subscribe to AIhub newsletter on substack



Related posts :

AI chatbots can effectively sway voters – in either direction

  12 Mar 2026
A short interaction with a chatbot can meaningfully shift a voter’s opinion about a presidential candidate or proposed policy.

Studying the properties of large language models: an interview with Maxime Meyer

  11 Mar 2026
What happens when you increase the prompt length in a LLM? In the latest interview in our AAAI Doctoral Consortium series, we sat down with Maxime, a PhD student in Singapore.

What the Moltbook experiment is teaching us about AI

An experimental social media platform where only AI bots can post reveals surprising lessons about artificial intelligence behaviour and safety.

The malleable mind: context accumulation drives LLM’s belief drift

  09 Mar 2026
LLMs change their "beliefs" over time, depending on the data they are given.

RWDS Big Questions: how do we balance innovation and regulation in the world of AI?

  06 Mar 2026
The panel explores the tensions, trade-offs and practical realities facing policymakers and data scientists alike.

Studying multiplicity: an interview with Prakhar Ganesh

  05 Mar 2026
What is multiplicity, and what implications does it have for fairness, privacy and interpretability in real-world systems?

Top AI ethics and policy issues of 2025 and what to expect in 2026

, and   04 Mar 2026
In the latest issue of AI Matters, a publication of ACM SIGAI, Larry Medsker summarised the year in AI ethics and policy, and looked ahead to 2026.

The greatest risk of AI in higher education isn’t cheating – it’s the erosion of learning itself

  03 Mar 2026
Will AI hollow out the pipeline of students, researchers and faculty that is the basis of today’s universities?



AIhub is supported by:







Subscribe to AIhub newsletter on substack




 















©2026.02 - Association for the Understanding of Artificial Intelligence